Thrombotic microangiopathies: a general approach to diagnosis and management

DM Arnold, CJ Patriquin, I Nazy - Cmaj, 2017 - cmaj.ca
ADAMTS13, and the inherited form is due to a genetic deficiency of ADAMTS13. In 1996,
Furlan and colleagues28 and Tsai29 independently found that patients with TTP had …

Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies

ML Troxell, JP Higgins, N Kambham - Advances in Anatomic …, 2016 - journals.lww.com
Cancer patients experience kidney injury from multiple sources, including the tumor itself,
diagnostic procedures, hypovolemia, infection, and drug exposure, superimposed upon …

[HTML][HTML] Thrombotic microangiopathy after allogeneic stem cell transplantation: a comparison of eculizumab therapy and conventional therapy

SR Bohl, F Kuchenbauer, S von Harsdorf… - Biology of Blood and …, 2017 - Elsevier
We report the results of a single-center analysis of a cohort of 39 patients treated between
1997 and 2016 for transplantion-associated thrombotic microangiopathy. We evaluated 2 …

High mortality in hematopoietic stem cell transplant-associated thrombotic microangiopathy with and without concomitant acute graft-versus-host disease

S Kraft, N Bollinger, B Bodenmann, D Heim… - Bone marrow …, 2019 - nature.com
Transplant-associated thrombotic microangiopathy (TA-TMA) remains a major complication
of allogeneic hematopoietic stem cell transplantation (allo-HSCT). We hypothesized that TA …

Eculizumab for transplant‐associated thrombotic microangiopathy in adult allogeneic stem cell transplant recipients

J Rudoni, A Jan, C Hosing, F Aung… - European Journal of …, 2018 - Wiley Online Library
Objective To evaluate response rates and survival in adults with transplant‐associated
thrombotic microangiopathy (TA‐TMA) after allogeneic hematopoietic stem cell …

[HTML][HTML] Early increase in complement terminal pathway activation marker sC5b-9 is predictive for the development of thrombotic microangiopathy after stem cell …

O Horváth, K Kállay, D Csuka, B Mező… - Biology of Blood and …, 2018 - Elsevier
Hematopoietic stem cell transplantation (HSCT)–associated thrombotic microangiopathy (TA-
TMA) is a multifactorial complication, and its prediction is largely unresolved. Our aim was to …

Validation of early increase in complement activation marker sC5b-9 as a predictive biomarker for the development of thrombotic microangiopathy after stem cell …

B Mezö, O Horváth, G Sinkovits, N Veszeli… - Frontiers in …, 2020 - frontiersin.org
Hematopoietic stem cell transplantation (HSCT)-associated thrombotic microangiopathy (TA-
TMA) is a multifactorial complication. Complement dysregulation may play an important role …

Immune suppression in allogeneic hematopoietic stem cell transplantation

TF Michniacki, SW Choi, DC Peltier - Pharmacology of …, 2021 - Springer
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative treatment for
high-risk hematologic disorders. There are multiple immune-mediated complications …

Use of defibrotide to treat adult patients with transplant-associated thrombotic microangiopathy

ME Martínez-Muñoz, R Forés, A Lario… - Bone Marrow …, 2019 - nature.com
Hematopoietic cell transplantation (HCT)-associated thrombotic microangiopathy (TA-TMA)
is an early and potentially life-threatening complication of the procedure. Multiple factors …

[HTML][HTML] Biobehavioral research and hematopoietic stem cell transplantation: expert review from the Biobehavioral Research Special Interest Group of the American …

DL Kelly, K Syrjala, M Taylor, KE Rentscher… - … and cellular therapy, 2021 - Elsevier
Hematopoietic stem cell transplantation (HCT) is a potentially curative treatment for many
hematologic conditions. Despite advances in conditioning and supportive measures …